Adrian G. Sacher
Adrian G. Sacher, MD, earned the IASLC Lung Cancer Fellowship Award for 2015-2016 and will study under the mentorship of Geoffrey R. Oxnard, MD, at the Dana-Farber Cancer Institute.
The use of new therapies in advanced non-small cell lung cancer (NSCLC) is limited by the need for several invasive biopsies to assess the genetic mutations present in a patient’s tumor. Noninvasive plasma genotyping is a novel blood test capable of overcoming this limitation. Dr. Sacher recently developed a new quantitative plasma genotyping test that can measure how much tumor DNA is in a blood sample and optimized it to detect key mutations in advanced NSCLC.
In his new study, Dr. Sacher plans to evaluate which factors affect the accuracy of the new blood test and if it can be used to quickly detect if a patient is responding to a new treatment. The goal is to identify the patient group in which this new blood test can be used most effectively to detect mutations in a patient’s tumor without a biopsy in order to select effect treatment. Additionally, this study will determine whether this blood test can show if a patient’s tumor is responding to a new treatment and it will translate this blood assay into clinical practice through a phase II trial designed to demonstrate the effectiveness of guiding treatment using rapid plasma genotyping in advanced NSCLC.
“I ultimately plan to develop a center of excellence to facilitate rapid development of novel targeted-therapies as well as the discovery and treatment of novel resistance mechanisms to existing targeting agents in lung cancer,” Dr. Sacher said.